NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Iantrek

Iantrek

Private
White Plains, New YorkHealthcare & Life Scienceshttps://iantrekmed.com/

Last Round

Debt

Apr 28, 2026

Est. Valuation

$95M

Total Funding Raised

$100.22M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Iantrek is an ophthalmic medical technology company that develops micro- and bio-interventional solutions for the surgical treatment of chronic eye diseases, with a primary focus on glaucoma.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

glaucoma managementophthalmic devicesbio-interventionalminimally invasive glaucoma surgeryMIGSmedical deviceophthalmologyaqueous humor outflowintraocular pressureambulatory surgery centerASCsurgical implantglaucoma surgery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iantrek Comps

Public and private peers based on sector, stage, and business model.

Iantrek comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Iantrek Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 28, 2026
Series CAug 20, 2025
Series BAug 30, 2022
Series A ExtensionOct 22, 2020

Key People

Founding team and executive leadership

Adam Szaronos

Chief Executive Officer

Executive Team

Sean Ianchulev

Founder, Chairman Of The Board, CEO

Founding Team

Mike H.

Chief Financial Officer

Executive Team

Iantrek Investors

Notable investors and investment history

Iantrek investors
InvestorRounds
U.S. Venture PartnersSeries C
aMoonSeries C
Trinity CapitalDebt
SectoralSeries C, Series B
Visionary VenturesSeries C, Series B
Civilization VenturesSeries C
JSD CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    $30M round led by Trinity Capital.

  • Mar 31, 2026

    Introducing AlloSpan Canal, a bio-reinforced platform for ophthalmic surgery.

Iantrek Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Iantrek Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Iantrek's valuation, stock price, and market status.

Firmographic Details

HeadquartersWhite Plains, New York
Employee Range79
Year Founded2019
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.